IMDX
Insight Molecular Diagnostics Inc.
3.90$
-0.8%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 58.5% | 57.4% | 85.8% | 87.9% | 83.5% | 90.8% | 57.6% | 16.6% | 24.5% | 25.5% | 14.3% | 33.5% | 59.4% | |
| 1.2% | 4.0% | 62.8% | 70.4% | 74.4% | 84.4% | 55.4% | 12.9% | 20.6% | 20.0% | 12.6% | 24.6% | 45.0% | |
| 57.1% | 55.6% | 82.8% | 85.9% | 81.8% | 88.9% | 56.3% | 14.1% | 21.2% | 20.4% | 12.6% | 24.6% | 45.0% | |
| – | – | – | – | – | – | – | 0.4% | 0.9% | 2.0% | 0.6% | 4.6% | 4.4% | |
| – | – | – | – | – | – | – | – | 0.2% | 2.1% | 0.0% | 1.2% | 1.7% | |
| – | – | – | – | – | – | – | 16.6% | 11.7% | 0.0% | – | – | – | |
| 20.7% | 23.2% | 9.7% | 6.8% | 7.3% | – | – | 27.1% | 38.7% | 61.6% | 75.6% | 41.6% | – | |
| 56.4% | 116.9% | 18.2% | 31.7% | 56.9% | 64.0% | 22.6% | 39.6% | 59.1% | 60.4% | 72.7% | 135.0% | 222.2% | |
| 56.4% | 116.9% | 18.2% | 29.6% | 43.6% | 58.4% | 11.1% | 16.2% | 8.8% | 12.1% | 9.6% | 20.7% | 46.9% | |
| 35.8% | 92.7% | – | 1.4% | 14.4% | 16.5% | 4.0% | 5.1% | 1.3% | 0.8% | 0.9% | 3.7% | 7.0% | |
| 1.2% | 2.3% | 2.2% | 2.9% | 1.7% | 1.7% | 1.2% | 0.8% | 1.1% | 1.3% | 1.3% | 6.5% | 9.9% | |
| 43.6% | -16.9% | 81.8% | 68.3% | 43.1% | 36.0% | 77.4% | 60.4% | 40.9% | 39.6% | 27.3% | -35.0% | -122.2% | |
| -125.7% | -242.3% | -189.6% | -244.4% | -535.2% | -749.3% | -235.2% | -223.2% | -117.7% | -260.4% | -387.1% | -999.2% | -1,556.0% | |
| 3.9% | 17.1% | 8.3% | 9.2% | 14.8% | 19.9% | 6.4% | 5.9% | 2.8% | 5.5% | 10.2% | 37.3% | 118.3% |
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.